Global Artificial Intelligence (AI) in Drug Discovery Market, By Component (Software, Service), Technology (Machine learning {Deep Learning}), Application Type (Target Identification), Therapeutic Area (Oncology), End-use (CRO), By Region and forecast till 2030.
Global Artificial Intelligence (AI) in Drug Discovery Market
Global Artificial Intelligence (AI) in Drug Discovery Market was valued at USD 885.32 million in 2022 and is slated to reach USD 1,39,88.71 million by 2030 at a CAGR of 23.87% from 2023-2030.
The use of technology powered by artificial intelligence (AI) to automate and hasten the drug development process is known as artificial intelligence (AI) in drug discovery. This covers duties including finding novel drug targets, creating new medications, figuring out how to make them more effectively, and maximising drug production. Artificial intelligence (AI) has the ability to analyse vast volumes of data, spot patterns, and make predictions that would be challenging or impossible for people to make on their own. Researchers may find novel medications more rapidly and effectively as a result of this.
Market Drivers
The demand for novel and efficient therapies is growing as more individuals are affected by chronic diseases. AI can be used to find novel therapeutic targets, create novel drug compounds, and forecast the toxicity and efficacy of possible treatments that would address market expansion. An estimated $1 billion or more goes into the development of a new medicine.
AI can assist in lowering the cost of drug development by automating processes like data analysis and compound screening. As a result of cutting down on the time needed for the drug discovery process, demand for artificial intelligence in drug discovery is increasing. This has led to the adoption of AI-powered technologies, which can assist in the discovery and development of novel drugs in days or months as opposed to the conventional method, which requires years.
The market for AI in drug discovery is anticipated to grow further as a result of rising healthcare spending and improvements in the healthcare system. AI has the potential to revolutionise drug discovery by drastically speeding up the R&D process, lowering the cost and duration of drug development, and increasing the likelihood that a medicine will be approved. Additionally, AI can improve the efficiency of drug repurposing studies.
The market is driven by an increase in cross-industry alliances and partnerships. A rise in financing for R&D activities, including AI technology in the field of drug research, and an increase in the significance of AI in drug discovery and development are expected to drive the growth of the global market. As a result, the market is being driven by an increase in cross-industry alliances and collaborations.
Market Restraints
The pharmaceutical industry is data-driven, and in order to train and produce reliable predictions, AI algorithms require a lot of data. The market expansion will be constrained by the dearth of high-quality data available for AI in drug discovery, particularly for uncommon diseases and neglected diseases. The legal framework for using AI in drug discovery is continually developing. Because there are questions regarding the efficacy and safety of AI-powered pharmaceuticals and because there are no clear regulatory requirements, the market is constrained.
The development and implementation of AI technologies can be costly. For poor nations and smaller businesses, this may be a hindrance.
Additionally, there is a lack of AI expertise in the pharmaceutical sector. Due to this, it may be challenging to locate and hire the talent required to create and implement AI-powered drug development solutions that impede market expansion.
Covid-19 Impact
The COVID-19 pandemic has had a conflicting effect on the market for AI in drug research. On the one hand, the pandemic has heightened the need for innovative, potent COVID-19 medications. As a result, systems for AI-based drug development have seen increased investment. On the other hand, the epidemic has also hampered the world's supply chain, making it challenging for some businesses to have access to the AI technologies they require. The implementation of artificial intelligence (AI) in drug discovery has been expedited by the COVID-19 pandemic. For instance, AI has been used to design new therapeutic compounds, find new pharmacological targets for COVID-19, and forecast the effectiveness and toxicity of potential treatment options.
Recent Development
To create and implement real-time AI applications, NVIDIA Corporation introduced Clara Holoscan MGX in March 2022. Clara Holoscan MGX enhances the Clara Holoscan platform by offering a comprehensive, medical-grade reference architecture as well as ongoing software support, accelerating innovation in the medical device sector. This will assist the business in achieving superior AI performance in the medical field for procedures, diagnostics, and drug development.
Restylane Lyft, a hyaluronic acid dermal filler for the treatment of moderate to severe face creases and folds, was given FDA approval by Galderma in February 2023.
AstraZeneca has chosen an additional novel target for Idiopathic Pulmonary Fibrosis (IPF) for its drug development portfolio, according to a milestone announcement made by Benevolent AI, a top clinical-stage AI-enabled drug discovery business, in May 2022. Benevolent AI will get a payment from AstraZeneca as a result. In two disease domains, IPF and chronic renal disease, the Benevolent Platform was used to identify this third novel target from the cooperation. AstraZeneca then verified the target and chose it for portfolio entry. The agreement with AstraZeneca was recently expanded to cover two additional disease areas, including systemic lupus erythematosus and heart failure, and was inked in January 2022. This has aided the business in fortifying its teamwork.
Market Segmentation
Global Artificial Intelligence (AI) in Drug Discovery Market is segmented into By Component, Technology, Application Type, Therapeutic Area, and End Use.
By Component such as Software Services. By Technology such as Machine Learning Deep Learning Supervised Learning Unsupervised Learning Other Machine Learning Technologies Other Technologies.
By Application Type such as Molecular library screening Target Identification Drug Optimization and Repurposing De novo Drug Designing Preclinical Testing. By Therapeutic Area such as Oncology Neurodegenerative Diseases Inflammatory Infectious Diseases Metabolic Diseases Rare Diseases Cardiovascular Diseases Other Therapeutic Areas. By End Use such as Pharmaceutical and Biotechnology Companies Contract Research Organization (CROs).
Regional Analysis
The market is dominated by North America. The market growth is anticipated to be boosted by the rising R&D spending and adoption of AI technology in the North American area over the past several years. Due to the significant presence of AI technology suppliers like IBM, Google, Microsoft, and others, the U.S. leads the region of North America.
Key Players
This report includes a list of numerous Key Players, NVIDIA Corporation, IBM Corp., Atomwise Inc., Microsoft, Benevolent AI, Aria Pharmaceuticals, Inc., DEEP GENOMICS, Exscientia, Cloud, Insilico Medicine, Cyclica, NuMedii, Inc., Envisagenics, Owkin Inc., BERG LLC, Schrödinger, Inc., XtalPi Inc. and BIOAGE Inc.
Market Taxonomy
By Component
By Technology
By Application Type
By Therapeutic Area
By End-use
By Region
Global Artificial Intelligence (AI) in Drug Discovery Market
1 Introduction
1.1 Objective of the Study
1.2 Market Definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Artificial Intelligence (AI) in Drug Discovery Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to Recent Energy Crisis
4.2.5 Cumulative Impact due to Nearing Economic Downturn
4.2.6 Post Covid-19 World Supply & Demand Conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Artificial Intelligence (AI) in Drug Discovery Market, By Component
5.1 Y-o-Y Growth Comparison, By Component
5.2 Global Artificial Intelligence (AI) in Drug Discovery Market Share Analysis, By Component
5.3 Global Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Component
5.3.1 Software
5.3.2 Services
6 Global Artificial Intelligence (AI) in Drug Discovery Market, By Technology
6.1 Y-o-Y Growth Comparison, By Technology
6.2 Global Artificial Intelligence (AI) in Drug Discovery Market Share Analysis, By Technology
6.3 Global Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Technology
6.3.1 Machine Learning
6.3.2 Deep Learning
6.3.3 Supervised Learning
6.3.4 Unsupervised Learning
6.3.5 Other Machine Learning Technologies
6.3.6 Other Technologies
7 Global Artificial Intelligence (AI) in Drug Discovery Market, By Application Type
7.1 Y-o-Y Growth Comparison, By Application Type
7.2 Global Artificial Intelligence (AI) in Drug Discovery Market Share Analysis, By Application Type
7.3 Global Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Application Type
7.3.1 Molecular library screening
7.3.2 Target Identification
7.3.3 Drug Optimization and Repurposing
7.3.4 De novo Drug Designing
7.3.5 Preclinical Testing
8 Global Artificial Intelligence (AI) in Drug Discovery Market, By Therapeutic Area
8.1 Y-o-Y Growth Comparison, By Therapeutic Area
8.2 Global Artificial Intelligence (AI) in Drug Discovery Market Share Analysis, By Therapeutic Area
8.3 Global Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Therapeutic Area
8.3.1 Oncology
8.3.2 neurodegenerative diseases
8.3.3 Inflammatory
8.3.4 Infectious Diseases
8.3.5 Metabolic Diseases
8.3.6 Rare Diseases
8.3.7 cardiovascular diseases
8.3.8 Other Therapeutic Areas
9 Global Artificial Intelligence (AI) in Drug Discovery Market, By End User
9.1 Y-o-Y Growth Comparison, By End User
9.2 Global Artificial Intelligence (AI) in Drug Discovery Market Share Analysis, By End User
9.3 Global Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By End User
9.3.1 Pharmaceutical and Biotechnology Companies
9.3.2 Contract Research Organization (CROs).
10 Global Artificial Intelligence (AI) in Drug Discovery Market, By Region
10.1 Global Artificial Intelligence (AI) in Drug Discovery Market Share Analysis, By Region
10.2 Global Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Region
10.3 Global Artificial Intelligence (AI) in Drug Discovery Market Trends and Forecast, By Region
11 North America Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 North America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Component
11.3 North America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Technology
11.4 North America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Application Type
11.5 North America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Therapeutic Area
11.6 North America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By End User
11.7 North America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Country
11.7.1 U.S.
11.7.1.1 Market Size and Forecast, By Component
11.7.1.2 Market Size and Forecast, By Technology
11.7.1.3 Market Size and Forecast, By Application Type
11.7.1.4 Market Size and Forecast, By Therapeutic Area
11.7.1.5 Market Size and Forecast, By End User
11.7.2 Canada
11.7.2.1 Market Size and Forecast, By Component
11.7.2.2 Market Size and Forecast, By Technology
11.7.2.3 Market Size and Forecast, By Application Type
11.7.2.4 Market Size and Forecast, By Therapeutic Area
11.7.2.5 Market Size and Forecast, By End User
11.7.3 Mexico
11.7.3.1 Market Size and Forecast, By Component
11.7.3.2 Market Size and Forecast, By Technology
11.7.3.3 Market Size and Forecast, By Application Type
11.7.3.4 Market Size and Forecast, By Therapeutic Area
11.7.3.5 Market Size and Forecast, By End User
12 Europe Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Component
12.3 Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Technology
12.4 Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Application Type
12.5 Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Therapeutic Area
12.6 Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By End User
12.7 Europe Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Country
12.7.1.1 Market Size and Forecast, By Component
12.7.1.2 Market Size and Forecast, By Technology
12.7.1.3 Market Size and Forecast, By Application Type
12.7.1.4 Market Size and Forecast, By Therapeutic Area
12.7.1.5 Market Size and Forecast, By End User
12.7.2 France
12.7.2.1 Market Size and Forecast, By Component
12.7.2.2 Market Size and Forecast, By Technology
12.7.2.3 Market Size and Forecast, By Application Type
12.7.2.4 Market Size and Forecast, By Therapeutic Area
12.7.2.5 Market Size and Forecast, By End User
12.7.3 UK
12.7.3.1 Market Size and Forecast, By Component
12.7.3.2 Market Size and Forecast, By Technology
12.7.3.3 Market Size and Forecast, By Application Type
12.7.3.4 Market Size and Forecast, By Therapeutic Area
12.7.3.5 Market Size and Forecast, By End User
12.7.4 Russia
12.7.4.1 Market Size and Forecast, By Component
12.7.4.2 Market Size and Forecast, By Technology
12.7.4.3 Market Size and Forecast, By Application Type
12.7.4.4 Market Size and Forecast, By Therapeutic Area
12.7.4.5 Market Size and Forecast, By End User
12.7.5 Italy
12.7.5.1 Market Size and Forecast, By Component
12.7.5.2 Market Size and Forecast, By Technology
12.7.5.3 Market Size and Forecast, By Application Type
12.7.5.4 Market Size and Forecast, By Therapeutic Area
12.7.5.5 Market Size and Forecast, By End User
12.7.6 Spain
12.7.6.1 Market Size and Forecast, By Component
12.7.6.2 Market Size and Forecast, By Technology
12.7.6.3 Market Size and Forecast, By Application Type
12.7.6.4 Market Size and Forecast, By Therapeutic Area
12.7.6.5 Market Size and Forecast, By End User
12.7.7 Rest of Europe
12.7.7.1 Market Size and Forecast, By Component
12.7.7.2 Market Size and Forecast, By Technology
12.7.7.3 Market Size and Forecast, By Application Type
12.7.7.4 Market Size and Forecast, By Therapeutic Area
12.7.7.5 Market Size and Forecast, By End User
13 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Component
13.3 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Technology
13.4 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Application Type
13.5 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Therapeutic Area
13.6 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By End User
13.7 Asia Pacific Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Country
13.7.1 China
13.7.1.1 Market Size and Forecast, By Component
13.7.1.2 Market Size and Forecast, By Technology
13.7.1.3 Market Size and Forecast, By Application Type
13.7.1.4 Market Size and Forecast, By Therapeutic Area
13.7.1.5 Market Size and Forecast, By End User
13.7.2 Japan
13.7.2.1 Market Size and Forecast, By Component
13.7.2.2 Market Size and Forecast, By Technology
13.7.2.3 Market Size and Forecast, By Application Type
13.7.2.4 Market Size and Forecast, By Therapeutic Area
13.7.2.5 Market Size and Forecast, By End User
13.7.3 India
13.7.3.1 Market Size and Forecast, By Component
13.7.3.2 Market Size and Forecast, By Technology
13.7.3.3 Market Size and Forecast, By Application Type
13.7.3.4 Market Size and Forecast, By Therapeutic Area
13.7.3.5 Market Size and Forecast, By End User
13.7.4 South Korea
13.7.4.1 Market Size and Forecast, By Component
13.7.4.2 Market Size and Forecast, By Technology
13.7.4.3 Market Size and Forecast, By Application Type
13.7.4.4 Market Size and Forecast, By Therapeutic Area
13.7.4.5 Market Size and Forecast, By End User
13.7.5 Australia
13.7.5.1 Market Size and Forecast, By Component
13.7.5.2 Market Size and Forecast, By Technology
13.7.5.3 Market Size and Forecast, By Application Type
13.7.5.4 Market Size and Forecast, By Therapeutic Area
13.7.5.5 Market Size and Forecast, By End User
13.7.6 New Zealand
13.7.6.1 Market Size and Forecast, By Component
13.7.6.2 Market Size and Forecast, By Technology
13.7.6.3 Market Size and Forecast, By Application Type
13.7.6.4 Market Size and Forecast, By Therapeutic Area
13.7.6.5 Market Size and Forecast, By End User
13.7.7 Singapore
13.7.7.1 Market Size and Forecast, By Component
13.7.7.2 Market Size and Forecast, By Technology
13.7.7.3 Market Size and Forecast, By Application Type
13.7.7.4 Market Size and Forecast, By Therapeutic Area
13.7.7.5 Market Size and Forecast, By End User
13.7.8 Malaysia
13.7.8.1 Market Size and Forecast, By Component
13.7.8.2 Market Size and Forecast, By Technology
13.7.8.3 Market Size and Forecast, By Application Type
13.7.8.4 Market Size and Forecast, By Therapeutic Area
13.7.8.5 Market Size and Forecast, By End User
13.7.9 Rest of Asia
13.7.9.1 Market Size and Forecast, By Component
13.7.9.2 Market Size and Forecast, By Technology
13.7.9.3 Market Size and Forecast, By Application Type
13.7.9.4 Market Size and Forecast, By Therapeutic Area
13.7.9.5 Market Size and Forecast, By End User
14 Latin America Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Component
14.3 Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Technology
14.4 Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Application Type
14.5 Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Therapeutic Area
14.6 Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By End User
14.7 Latin America Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Country
14.7.1 Brazil
14.7.1.1 Market Size and Forecast, By Component
14.7.1.2 Market Size and Forecast, By Technology
14.7.1.3 Market Size and Forecast, By Application Type
14.7.1.4 Market Size and Forecast, By Therapeutic Area
14.7.1.5 Market Size and Forecast, By End User
14.7.2 Argentina
14.7.2.1 Market Size and Forecast, By Component
14.7.2.2 Market Size and Forecast, By Technology
14.7.2.3 Market Size and Forecast, By Application Type
14.7.2.4 Market Size and Forecast, By Therapeutic Area
14.7.2.5 Market Size and Forecast, By End User
14.7.3 Colombia
14.7.3.1 Market Size and Forecast, By Component
14.7.3.2 Market Size and Forecast, By Technology
14.7.3.3 Market Size and Forecast, By Application Type
14.7.3.4 Market Size and Forecast, By Therapeutic Area
14.7.3.5 Market Size and Forecast, By End User
14.7.4 Peru
14.7.4.1 Market Size and Forecast, By Component
14.7.4.2 Market Size and Forecast, By Technology
14.7.4.3 Market Size and Forecast, By Application Type
14.7.4.4 Market Size and Forecast, By Therapeutic Area
14.7.4.5 Market Size and Forecast, By End User
14.7.5 Chile
14.7.5.1 Market Size and Forecast, By Component
14.7.5.2 Market Size and Forecast, By Technology
14.7.5.3 Market Size and Forecast, By Application Type
14.7.5.4 Market Size and Forecast, By Therapeutic Area
14.7.5.5 Market Size and Forecast, By End User
14.7.6 Venezuela
14.7.6.1 Market Size and Forecast, By Component
14.7.6.2 Market Size and Forecast, By Technology
14.7.6.3 Market Size and Forecast, By Application Type
14.7.6.4 Market Size and Forecast, By Therapeutic Area
14.7.6.5 Market Size and Forecast, By End User
14.7.7 Rest of Latin America
14.7.7.1 Market Size and Forecast, By Component
14.7.7.2 Market Size and Forecast, By Technology
14.7.7.3 Market Size and Forecast, By Application Type
14.7.7.4 Market Size and Forecast, By Therapeutic Area
14.7.7.5 Market Size and Forecast, By End User
15 Middle East Artificial Intelligence (AI) in Drug Discovery Market Analysis and Forecast (2023-2030)
15.1 Introduction
15.2 Middle East Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Component
15.3 Middle East Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Technology
15.4 Middle East Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Application Type
15.5 Middle East Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Therapeutic Area
15.6 Middle East Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By End User
15.7 Middle East Artificial Intelligence (AI) in Drug Discovery Market Size and Forecast, By Country
15.7.1 Saudi Arabia
15.7.1.1 Market Size and Forecast, By Component
15.7.1.2 Market Size and Forecast, By Technology
15.7.1.3 Market Size and Forecast, By Application Type
15.7.1.4 Market Size and Forecast, By Therapeutic Area
15.7.1.5 Market Size and Forecast, By End User
15.7.2 UAE
15.7.2.1 Market Size and Forecast, By Component
15.7.2.2 Market Size and Forecast, By Technology
15.7.2.3 Market Size and Forecast, By Application Type
15.7.2.4 Market Size and Forecast, By Therapeutic Area
15.7.2.5 Market Size and Forecast, By End User
15.7.3 Egypt
15.7.3.1 Market Size and Forecast, By Component
15.7.3.2 Market Size and Forecast, By Technology
15.7.3.3 Market Size and Forecast, By Application Type
15.7.3.4 Market Size and Forecast, By Therapeutic Area
15.7.3.5 Market Size and Forecast, By End User
15.7.4 Kuwait
15.7.4.1 Market Size and Forecast, By Component
15.7.4.2 Market Size and Forecast, By Technology
15.7.4.3 Market Size and Forecast, By Application Type
15.7.4.4 Market Size and Forecast, By Therapeutic Area
15.7.4.5 Market Size and Forecast, By End User
15.7.5.1 Market Size and Forecast, By Component
15.7.5.2 Market Size and Forecast, By Technology
15.7.5.3 Market Size and Forecast, By Application Type
15.7.5.4 Market Size and Forecast, By Therapeutic Area
15.7.5.5 Market Size and Forecast, By End User
15.7.6 Rest of Middle East & Africa
15.7.6.1 Market Size and Forecast, By Component
15.7.6.2 Market Size and Forecast, By Technology
15.7.6.3 Market Size and Forecast, By Application Type
15.7.6.4 Market Size and Forecast, By Therapeutic Area
15.7.6.5 Market Size and Forecast, By End User
16 Competitive Analysis
16.1 Competition Dashboard
16.2 Market share Analysis of Top Vendors
16.3 Key Development Strategies
17 Company Profiles
17.1 IBM Corp
17.1.2 Offerings
17.1.3 Key Financials
17.1.4 Business Segment & Geographic Overview
17.1.5 Key Market Developments
17.1.6 Key Strategies
17.2 NVIDIA Corporation
17.2.1 Overview
17.2.2 Offerings
17.2.3 Key Financials
17.2.4 Business Segment & Geographic Overview
17.2.5 Key Market Developments
17.2.6 Key Strategies
17.3 Atomwise Inc
17.3.1 Overview
17.3.2 Offerings
17.3.3 Key Financials
17.3.4 Business Segment & Geographic Overview
17.3.5 Key Market Developments
17.3.6 Key Strategies
17.4 Microsoft, Benevolent AI
17.4.1 Overview
17.4.1 Overview
17.4.2 Offerings
17.4.3 Key Financials
17.4.4 Business Segment & Geographic Overview
17.4.5 Key Market Developments
17.4.6 Key Strategies
17.5 Aria Pharmaceuticals
17.5.1 Overview
17.5.2 Offerings
17.5.3 Key Financials
17.5.4 Business Segment & Geographic Overview
17.5.5 Key Market Developments
17.5.6 Key Strategies
17.6 DEEP GENOMICS
17.6.1 Overview
17.6.2 Offerings
17.6.3 Key Financials
17.6.4 Business Segment & Geographic Overview
17.6.5 Key Market Developments
17.6.6 Key Strategies
17.7 Exscientia
17.7.1 Overview
17.7.2 Offerings
17.7.3 Key Financials
17.7.4 Business Segment & Geographic Overview
17.7.5 Key Market Developments
17.7.6 Key Strategies
17.8 Alphabet (DeepMind)
17.8.1 Overview
17.8.2 Offerings
17.8.3 Key Financials
17.8.4 Business Segment & Geographic Overview
17.8.5 Key Market Developments
17.8.6 Key Strategies
17.9 Insilico Medicine
17.9.1 Overview
17.9.2 Offerings
17.9.3 Key Financials
17.9.4 Business Segment & Geographic Overview
17.9.5 Key Market Developments
17.9.6 Key Strategies
17.10 Cyclica
17.10.1 Overview
17.10.2 Offerings
17.10.3 Key Financials
17.10.4 Business Segment & Geographic Overview
17.10.5 Key Market Developments
17.10.6 Key Strategies
